Harvey Capital Management Inc Halozyme Therapeutics, Inc. Transaction History
Harvey Capital Management Inc
- $380 Million
- Q1 2025
A detailed history of Harvey Capital Management Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Harvey Capital Management Inc holds 149,175 shares of HALO stock, worth $7.88 Million. This represents 2.5% of its overall portfolio holdings.
Number of Shares
149,175
Previous 185,435
19.55%
Holding current value
$7.88 Million
Previous $8.87 Million
7.37%
% of portfolio
2.5%
Previous 2.1%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
594Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$931 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$678 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$320 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$206 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$194 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.36B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...